EUVIMEDEUVIMED entdecken
Fallbericht

Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion

Jennifer Marsh, Angela T Logan, Erin P Bilgili, Lyndsey J Bowman, Allyssa R Webb

American Journal of Health-System Pharmacy · 2024

DOI: 10.1093/ajhp/zxae032 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Health-System Pharmacy, 2024. Verfasst von Jennifer Marsh und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of South Florida Taneja College of Pharmacy, Tampa, FL, USA. Hauptthemen laut MEDLINE: Phenytoin, Tacrolimus, Drug Interactions, Ritonavir. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Nirmatrelvir/ritonavir is one of few options for outpatient treatment of COVID-19, but its use has been limited in transplant recipients due to significant drug interactions with immunosuppressants. Tacrolimus toxicity is possible when the drug is coadministered with nirmatrelvir/ritonavir and may require urgent reduction of tacrolimus levels. This case series describes the use of phenytoin for enzyme induction in 5 adult solid organ transplant recipients with supratherapeutic tacrolimus levels resulting from coadministration with nirmatrelvir/ritonavir. Summary Solid organ transplant recipients are at high risk for complications related to COVID-19. Outpatient treatment options are limited, and therapeutic drug monitoring is complex in patients requiring quarantine. The 5 solid organ transplant recipients described herein were initiated on nirmatrelvir/ritonavir in the outpatient setting and subsequently presented with supratherapeutic tacrolimus concentrations greater than 59 ng/mL and developed signs and symptoms of tacrolimus toxicity. In all patients, nirmatrelvir/ritonavir and tacrolimus were discontinued, and oral phenytoin (200-400 mg/day) was given for 2 to 4 days. Tacrolimus was resumed once tacrolimus levels decreased to appropriate levels.

Conclusion

These observations demonstrate that metabolism induction using phenytoin may be a useful strategy in the setting of supratherapeutic tacrolimus levels resulting from concomitant administration with nirmatrelvir/ritonavir.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenytoinTacrolimusDrug InteractionsRitonavirImmunosuppressive AgentsHumansMiddle AgedMaleFemaleCOVID-19 Drug TreatmentAgedAdultDrug MonitoringCytochrome P-450 CYP3A InducersTransplant Recipients

Stichwörter der Autor:innen

COVID-19drug interactionnirmatrelvir/ritonavirphenytointacrolimus

Substanzen

PhenytoinTacrolimusRitonavirImmunosuppressive AgentsCytochrome P-450 CYP3A Inducers

Autor:innen und Institutionen

  • University of South Florida Taneja College of Pharmacy, Tampa, FL, USA.
  • Tampa General Hospital, Tampa, FL, USA.

Zitieren

APA

Marsh, J., Logan, A. T., Bilgili, E. P., Bowman, L. J., & Webb, A. R. (2024). Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxae032

Vancouver

Marsh J, Logan AT, Bilgili EP, Bowman LJ, Webb AR. Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion. American Journal of Health-System Pharmacy. 2024. doi:10.1093/ajhp/zxae032

BibTeX
@article{Marsh2024,
  author = {Marsh, Jennifer and Logan, Angela T and Bilgili, Erin P and Bowman, Lyndsey J and Webb, Allyssa R},
  title = {Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion},
  journal = {American Journal of Health-System Pharmacy},
  year = {2024},
  doi = {10.1093/ajhp/zxae032}
}
Kostenlos starten →